These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1353 related articles for article (PubMed ID: 33261845)
21. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening. Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740 [TBL] [Abstract][Full Text] [Related]
22. Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19. Faheem ; Kumar BK; Sekhar KVGC; Kunjiappan S; Jamalis J; Balaña-Fouce R; Tekwani BL; Sankaranarayanan M Bioorg Chem; 2020 Nov; 104():104269. PubMed ID: 32947136 [TBL] [Abstract][Full Text] [Related]
23. Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19. von Hentig N Eur J Clin Pharmacol; 2021 Sep; 77(9):1297-1307. PubMed ID: 33660020 [TBL] [Abstract][Full Text] [Related]
24. COVID-19: Potential Repurposing Drugs. Leowattana W Infect Disord Drug Targets; 2022; 22(1):e110122191924. PubMed ID: 33645490 [TBL] [Abstract][Full Text] [Related]
25. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. Simonis A; Theobald SJ; Fätkenheuer G; Rybniker J; Malin JJ EMBO Mol Med; 2021 Jan; 13(1):e13105. PubMed ID: 33015938 [TBL] [Abstract][Full Text] [Related]
26. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. Aherfi S; Pradines B; Devaux C; Honore S; Colson P; Scola B; Raoult D Future Microbiol; 2021 Nov; 16():1341-1370. PubMed ID: 34755538 [TBL] [Abstract][Full Text] [Related]
27. Repurposing of potential antiviral drugs against RNA-dependent RNA polymerase of SARS-CoV-2 by computational approach. Gangadharan S; Ambrose JM; Rajajagadeesan A; Kullappan M; Patil S; Gandhamaneni SH; Veeraraghavan VP; Nakkella AK; Agarwal A; Jayaraman S; Surapaneni KM J Infect Public Health; 2022 Nov; 15(11):1180-1191. PubMed ID: 36240528 [TBL] [Abstract][Full Text] [Related]
28. Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19. Apaydın ÇB; Çınar G; Cihan-Üstündağ G Curr Drug Targets; 2021; 22(17):1986-2005. PubMed ID: 33588727 [TBL] [Abstract][Full Text] [Related]
29. Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review. Kröker A; Tirzīte M Respir Res; 2021 Nov; 22(1):304. PubMed ID: 34838020 [TBL] [Abstract][Full Text] [Related]
30. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19. Kumar P; Sah AK; Tripathi G; Kashyap A; Tripathi A; Rao R; Mishra PC; Mallick K; Husain A; Kashyap MK Mol Cell Biochem; 2021 Feb; 476(2):553-574. PubMed ID: 33029696 [TBL] [Abstract][Full Text] [Related]
31. A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval. Ashour NA; Abo Elmaaty A; Sarhan AA; Elkaeed EB; Moussa AM; Erfan IA; Al-Karmalawy AA Drug Des Devel Ther; 2022; 16():685-715. PubMed ID: 35321497 [TBL] [Abstract][Full Text] [Related]
32. Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs. More SA; Patil AS; Sakle NS; Mokale SN Virology; 2021 Mar; 555():10-18. PubMed ID: 33421743 [TBL] [Abstract][Full Text] [Related]
33. Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century. Sanghai N; Shafiq K; Tranmer GK Mini Rev Med Chem; 2021; 21(1):3-9. PubMed ID: 32838716 [TBL] [Abstract][Full Text] [Related]
34. MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs. Feng Z; Chen M; Xue Y; Liang T; Chen H; Zhou Y; Nolin TD; Smith RB; Xie XQ Brief Bioinform; 2021 Mar; 22(2):946-962. PubMed ID: 33078827 [TBL] [Abstract][Full Text] [Related]
35. Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies. Daoud S; Alabed SJ; Dahabiyeh LA Acta Pharm; 2021 Jun; 71(2):163-174. PubMed ID: 33151166 [TBL] [Abstract][Full Text] [Related]
36. Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay. Jang WD; Jeon S; Kim S; Lee SY Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34234012 [TBL] [Abstract][Full Text] [Related]
37. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing. Pathak N; Chen YT; Hsu YC; Hsu NY; Kuo CJ; Tsai HP; Kang JJ; Huang CH; Chang SY; Chang YH; Liang PH; Yang JM ACS Nano; 2021 Jan; 15(1):857-872. PubMed ID: 33373194 [TBL] [Abstract][Full Text] [Related]
38. State-of-the-art Tools to Elucidate the Therapeutic Potential of TAT-peptide (TP) Conjugated Repurposing Drug Against SARS-CoV-2 Spike Glycoproteins. Ansari MA; Alomary MN; Jamal QMS; Almoshari Y; Salawi A; Almahmoud SA; Khan J Curr Pharm Des; 2022; 28(46):3706-3719. PubMed ID: 36278465 [TBL] [Abstract][Full Text] [Related]
39. Potential COVID-19 Therapies from Computational Repurposing of Drugs and Natural Products against the SARS-CoV-2 Helicase. Piplani S; Singh P; Winkler DA; Petrovsky N Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887049 [TBL] [Abstract][Full Text] [Related]
40. Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19? Dallocchio RN; Dessì A; De Vito A; Delogu G; Serra PA; Madeddu G Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2435-2448. PubMed ID: 33755983 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]